Cancer drug combo trial ends early after just one patient
NCT ID NCT06130254
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This early-stage study aimed to test the safety of combining two targeted drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific KRAS G12C mutation. The trial focused on certain cancers like gynecological, breast, pancreatic, and a type of lung cancer. However, the study was terminated early after enrolling only one participant, so no conclusions about the combination's safety or effectiveness could be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.